These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 18759308)

  • 21. Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase.
    Mandell BF; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2018 Dec; 20(1):286. PubMed ID: 30594229
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A multicentre, efficacy and safety study of methotrexate to increase response rates in patients with uncontrolled gout receiving pegloticase (MIRROR): 12-month efficacy, safety, immunogenicity, and pharmacokinetic findings during long-term extension of an open-label study.
    Botson JK; Tesser JRP; Bennett R; Kenney HM; Peloso PM; Obermeyer K; Song Y; LaMoreaux B; Zhao L; Xin Y; Chamberlain J; Ramanathan S; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Aug; 24(1):208. PubMed ID: 36008814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pegloticase: in treatment-refractory chronic gout.
    Lyseng-Williamson KA
    Drugs; 2011 Nov; 71(16):2179-92. PubMed ID: 22035516
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-hoc analysis of pegloticase pivotal trials in chronic refractory gout: relationship between fluctuations in plasma urate levels and acute flares.
    Mandell BF; Fields TR; Edwards NL; Yeo AE; Lipsky PE
    Clin Exp Rheumatol; 2021; 39(5):1085-1092. PubMed ID: 33427618
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase I trial of subcutaneous PEGylated urate oxidase.
    Ganson NJ; Kelly SJ; Scarlett E; Sundy JS; Hershfield MS
    Arthritis Res Ther; 2006; 8(1):R12. PubMed ID: 16356199
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegloticase. An excessively dangerous and inadequately evaluated hypouricaemic drug.
    Prescrire Int; 2014 Jul; 23(151):173-6. PubMed ID: 25162087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The COMPARE head-to-head, randomized controlled trial of SEL-212 (pegadricase plus rapamycin-containing nanoparticle, ImmTOR™) versus pegloticase for refractory gout.
    Baraf HSB; Khanna PP; Kivitz AJ; Strand V; Choi HK; Terkeltaub R; Dalbeth N; DeHaan W; Azeem R; Traber PG; Keenan RT
    Rheumatology (Oxford); 2024 Apr; 63(4):1058-1067. PubMed ID: 37449908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial.
    Botson JK; Obermeyer K; LaMoreaux B; Zhao L; Weinblatt ME; Peterson J
    Arthritis Res Ther; 2022 Dec; 24(1):281. PubMed ID: 36575505
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PEG-uricase in the management of treatment-resistant gout and hyperuricemia.
    Sherman MR; Saifer MG; Perez-Ruiz F
    Adv Drug Deliv Rev; 2008 Jan; 60(1):59-68. PubMed ID: 17826865
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rilonacept (interleukin-1 trap) in the prevention of acute gout flares during initiation of urate-lowering therapy: results of a phase II randomized, double-blind, placebo-controlled trial.
    Schumacher HR; Sundy JS; Terkeltaub R; Knapp HR; Mellis SJ; Stahl N; Yancopoulos GD; Soo Y; King-Davis S; Weinstein SP; Radin AR;
    Arthritis Rheum; 2012 Mar; 64(3):876-84. PubMed ID: 22223180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Urate-oxidase for the treatment of tophaceous gout in heart transplant recipients. A report of three cases.
    Rozenberg S; Roche B; Dorent R; Koeger AC; Borget C; Wrona N; Bourgeois P
    Rev Rhum Engl Ed; 1995 May; 62(5):392-4. PubMed ID: 7655872
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Update on emerging urate-lowering therapies.
    Chohan S; Becker MA
    Curr Opin Rheumatol; 2009 Mar; 21(2):143-9. PubMed ID: 19339925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Randomized, Placebo-Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings.
    Botson JK; Saag K; Peterson J; Parikh N; Ong S; La D; LoCicero K; Obermeyer K; Xin Y; Chamberlain J; LaMoreaux B; Verma S; Sainati S; Grewal S; Majjhoo A; Tesser JRP; Weinblatt ME
    Arthritis Rheumatol; 2023 Feb; 75(2):293-304. PubMed ID: 36099211
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Reduction of plasma urate levels in the cockerel with polyethylene glycol-uricase.
    Abuchowski A; Karp D; Davis FF
    J Pharmacol Exp Ther; 1981 Nov; 219(2):352-4. PubMed ID: 7288624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resolution of gouty tophi after twelve weeks of pegloticase treatment.
    Baraf HS; Matsumoto AK; Maroli AN; Waltrip RW
    Arthritis Rheum; 2008 Nov; 58(11):3632-4. PubMed ID: 18975338
    [No Abstract]   [Full Text] [Related]  

  • 36. Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout.
    Calabrese LH; Kavanaugh A; Yeo AE; Lipsky PE
    Arthritis Res Ther; 2017 Aug; 19(1):191. PubMed ID: 28818095
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rilonacept (interleukin-1 trap) for prevention of gout flares during initiation of uric acid-lowering therapy: results from a phase III randomized, double-blind, placebo-controlled, confirmatory efficacy study.
    Schumacher HR; Evans RR; Saag KG; Clower J; Jennings W; Weinstein SP; Yancopoulos GD; Wang J; Terkeltaub R
    Arthritis Care Res (Hoboken); 2012 Oct; 64(10):1462-70. PubMed ID: 22549879
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout.
    Becker MA; Schumacher HR; MacDonald PA; Lloyd E; Lademacher C
    J Rheumatol; 2009 Jun; 36(6):1273-82. PubMed ID: 19286847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy.
    Baraf HS; Becker MA; Gutierrez-Urena SR; Treadwell EL; Vazquez-Mellado J; Rehrig CD; Ottery FD; Sundy JS; Yood RA
    Arthritis Res Ther; 2013 Sep; 15(5):R137. PubMed ID: 24286509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
    Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
    Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.